Weekly Recap | Rallybio -0.12%, consensus target below spotWeekly Review·Aug 29 at 06:16 AMRLYB+0.27%
Rallybio (NASDAQ:RLYB) Releases Earnings Results, Beats Estimates By $8.81 EPSMarket Beat·Aug 7 at 12:11 AMRLYB+0.27%
Rallybio swings to Q2 net income of $43.67 million; operating loss narrows to $5.65 millionPUBT·Aug 6 at 12:05 PMRLYB+0.27%
Rallybio Corporation (NASDAQ:RLYB) Sees Significant Decline in Short InterestMarket Beat·Jul 27 at 07:00 AMRLYB+0.27%
Are DXLG, LAB, FHB, RLYB Obtaining Fair Deals for their Shareholders?PR Newswire·Jul 21 at 06:53 PMRLYB+0.27%LAB-0.10%
15:21 ET$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger--NCSM, PSBQ, LAB, and RLYBprnewswire·Jul 20 at 07:21 PMNCSM0.00%RLYB+0.27%
Are SUNE, RLYB, ASRT, TMHC Obtaining Fair Deals for their Shareholders?PR Newswire·Jun 9 at 05:19 PMTMHC0.00%SUNE-1.69%
<![CDATA[Pharma M&A Roundup: Servier Acquiring Edgewise Therapeutics' Muscular Dystrophy Business, Hanmi Enters Licensing Agreement with Eli Lilly, Avenzo Enters Merger Agreement with Rallybio]]>Pharmexec·Jun 1 at 01:42 PMEWTX+4.10%LLY-1.59%
